LCT waiting for minister

By Kate McDonald
Thursday, 26 June, 2008

Living Cell Technologies (ASX: LCT) expects to hear on or after August 8 whether it can proceed with a New Zealand trial of its encapsulated porcine islet cell product, DiabeCell.

The New Zealand Minister for Health, David Cunliffe, has sought independent advice from the country's National Health Committee (NHC) on whether to authorise the phase I/IIa clinical trial.

LCT said in a statement it had already received approval from NZ regulatory bodies such as the regional ethics committee, the Gene Technology Advisory Committee and International Accreditation New Zealand.

It has also received approval from Medsafe, the regulatory body that approved the manufacture for human use of encapsulated porcine cells.

LCT is currently running a small clinical trial at the Sklifosovsky Institute in Moscow.

Related News

Quitting smoking increases life expectancy even for seniors

Although the benefits of quitting smoking diminish with age, there are still substantial gains...

Stem cell transplants treat blindness in mini pigs

Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...

Sugary drinks raise cardiovascular disease risk, but occasional sweets don't

Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd